Mycophenolate Mofetil, Carnitine and Phosphodiesterase Type 5 Inhibitor, Three Potential Treatments for Resistant Proteinuria and for Slowing the Deterioration of Diabetic Nephropathy in Patients With Type II Diabetes Mellitus
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Mycophenolate mofetil (Primary) ; Carnitine; Type 5 cyclic nucleotide phosphodiesterase inhibitors
- Indications Diabetic nephropathies
- Focus Pharmacodynamics
Most Recent Events
- 05 Apr 2012 New trial record
- 29 Mar 2012 Biomarkers information updated